Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Postoperative GI Dysfunction and Nutrition in Malnourished Cancer Surgery Patients (GIDNUT)

31. Mai 2026 aktualisiert von: Arma Ltd.

Gastrointestinal Dysfunction, Nutritional Status, and Delirium in the Early Postoperative Period in Oncologic Surgical Patients With Pre-existing Malnutrition: A Prospective Two-Center Observational Cohort Study

This is a prospective two-center observational cohort study in adult patients undergoing major abdominal and/or pelvic oncologic surgery with pre-existing malnutrition. The study describes the course of postoperative gastrointestinal dysfunction and evaluates whether real-world exposure to parenteral serotonin as part of routine postoperative care is associated with a higher proportion of patients whose gastrointestinal dysfunction regresses to LIFE score less than or equal to 1 by postoperative day 5 (plus or minus 1 day), compared with patients not exposed to serotonin.

All treatment decisions, including the use of parenteral serotonin, metoclopramide, neostigmine, nutritional support, and other postoperative management, are made solely by the treating physicians in accordance with routine clinical practice. The protocol does not assign, randomize, require, or restrict any drug treatment; it records real-world care, daily LIFE assessments during postoperative days 1 through 7, nutritional status measures, body composition where available, delirium screening, complications, length of stay, and mortality.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Disease-related malnutrition and sarcopenia are common in patients undergoing major abdominal or pelvic oncologic surgery and are associated with worse postoperative outcomes, including more complications, prolonged hospital stay, and increased mortality. Postoperative gastrointestinal dysfunction may further impair tolerance of enteral nutrition and delay recovery, especially in patients with baseline malnutrition.

In routine practice at the participating centers, postoperative gastrointestinal dysfunction or functional ileus may be managed with different pharmacologic approaches, including metoclopramide, neostigmine, and in some patients parenteral serotonin. The choice of therapy, dose, timing, and duration is determined entirely by the treating clinicians according to routine care, approved labeling, and local institutional practice; no treatment is assigned by the protocol.

This study prospectively enrolls approximately 120 adult patients with histologically or cytologically confirmed malignancy who are scheduled for major abdominal and/or pelvic oncologic surgery and have pre-existing malnutrition defined by NRS-2002 score at least 3 plus at least one phenotypic and one etiologic GLIM criterion. Participants are observed from the preoperative period through discharge or postoperative day 30, whichever occurs first.

Exposure cohorts are defined after inclusion according to whether parenteral serotonin was actually received during the early postoperative period as part of routine care. The primary endpoint is the proportion of participants with regression of gastrointestinal dysfunction to LIFE score less than or equal to 1 by postoperative day 5 within the postoperative day 4 to 6 assessment window.

Secondary outcomes include the trajectory of LIFE scores during postoperative days 1 to 7, time to restoration of gastrointestinal motility, time to achievement of at least 60 to 70 percent of calculated energy requirements via enteral nutrition, changes in nutritional status and body composition, delirium incidence and duration, postoperative complications graded by Clavien-Dindo, infectious complications, ICU and hospital length of stay, and mortality. The study is exploratory and is intended to characterize real-world postoperative trajectories and generate effect-size estimates for future studies rather than provide definitive proof of treatment superiority.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

120

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

  • Russland
      • Saint Petersburg, Russland, 194291
        • North-Western District Scientific and Clinical Center named after L.G. Sokolov, FMBA of Russia

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Adult patients (≥18 years) with histologically or cytologically confirmed abdominal or pelvic malignancy scheduled for major oncologic surgery (radical or cytoreductive), with pre existing malnutrition (NRS 2002 ≥3 and ≥1 phenotypic + ≥1 etiologic GLIM criterion), and expected postoperative hospital stay ≥7 days.

Beschreibung

Inclusion Criteria:

  • Age ≥ 18 years.
  • Histologically confirmed malignant tumor of the abdomen or pelvis with planned radical or cytoreductive surgery.
  • Baseline malnutrition defined as NRS2002 ≥ 3 and at least one phenotypic and one etiologic GLIM criterion.
  • Expected postoperative hospitalization ≥ 7 days.
  • Ability to undergo baseline cognitive and nutritional assessments (MoCA, NRS2002, GLIM, PG-SGA) prior to surgery.
  • Signed informed consent for participation and data collection.

Exclusion Criteria:

  • Severe decompensated hepatic or renal failure rendering surgery infeasible.
  • Documented preexisting severe cognitive impairment or dementia precluding valid postoperative cognitive/delirium assessment (e.g., MoCA < 18 or documented dementia).
  • Pregnancy or breastfeeding.
  • Participation in another interventional randomized clinical trial within the prior 30 days that could confound outcomes.
  • Inability to ensure postoperative follow-up or reliable data collection (planned transfer without access, loss of contact).

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Serotonin Cohort
Participants who receive parenteral serotonin, such as serotonin adipinate, at any time during the early postoperative period as part of routine clinical management of postoperative gastrointestinal dysfunction or functional ileus, at the discretion of the treating physician. Exposure is observed and recorded; it is not assigned by protocol.
Arzneimittel: Serotonin (e.g., serotonin adipinate)
Parenteral serotonin administered postoperatively per treating physician's discretion. Dose, duration, and co-administration with other prokinetics recorded.
No Serotonin Cohort
Participants who do not receive parenteral serotonin during the index hospitalization. Other standard prokinetic agents, including metoclopramide or neostigmine, may be used according to routine clinical care. Exposure is observed and recorded; it is not assigned by protocol.
Arzneimittel: Standard Prokinetic Therapy (excluding serotonin)
Use of metoclopramide, neostigmine, or other prokinetics per local practice, without serotonin.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Proportion of participants with LIFE ≤ 1 by postoperative day 5 (POD5 ±1 day)
Zeitfenster: Postoperative day (POD) 5 ± 1 day (assessment window POD4-POD6)
The proportion of participants whose gastrointestinal dysfunction regresses to a Lausanne Intestinal Failure Estimation (LIFE) score of ≤1 within the assessment window (POD4-POD6). LIFE is assessed once daily from POD1 through POD7 using routine clinical parameters.
Postoperative day (POD) 5 ± 1 day (assessment window POD4-POD6)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Mean LIFE score from postoperative day 1 through postoperative day 7
Zeitfenster: Postoperative Days 1-7
Average of daily LIFE scores measured once per day from POD1 to POD7. LIFE is a composite clinical score of gastrointestinal dysfunction. Mean LIFE over this period will be compared between serotonin exposed and non exposed cohorts to describe the trajectory of GI function.
Postoperative Days 1-7
Time to restoration of gastrointestinal motility (first spontaneous bowel movement without clinical signs of significant GID)
Zeitfenster: From the date of surgery until the date of the first documented spontaneous bowel movement without clinically significant gastrointestinal dysfunction, assessed up to 30 days after surgery
Number of days from surgery to the first documented spontaneous bowel movement without clinically significant ongoing gastrointestinal dysfunction (as judged by the treating team and LIFE score).
From the date of surgery until the date of the first documented spontaneous bowel movement without clinically significant gastrointestinal dysfunction, assessed up to 30 days after surgery
Number of participants with at least one episode of delirium
Zeitfenster: From postoperative day 0 through postoperative day 10 after surgery or until hospital discharge, whichever occurs first.
Proportion of participants with at least one positive delirium assessment using CAM ICU or ICDSC during ICU and ward stay.
From postoperative day 0 through postoperative day 10 after surgery or until hospital discharge, whichever occurs first.
Number of delirium days
Zeitfenster: From postoperative day 0 through postoperative day 10 after surgery or until hospital discharge, whichever occurs first.
Total number of calendar days with positive CAM-ICU or ICDSC assessments.
From postoperative day 0 through postoperative day 10 after surgery or until hospital discharge, whichever occurs first.
Frequency of surgical complications (Clavien-Dindo, grade II-V)
Zeitfenster: Up to 30 days after surgery
Proportion of participants who develop at least one postoperative complication of Clavien-Dindo grade II or higher; separate reporting of grade III-V complications.
Up to 30 days after surgery
Frequency of infectious complications
Zeitfenster: Up to 30 days after surgery
Proportion of participants with clinically diagnosed infectious complications (e.g., surgical site infection, pneumonia, intra abdominal abscess, sepsis) during the index hospitalization.
Up to 30 days after surgery
ICU length of stay (days) and hospital length of stay (days)
Zeitfenster: Up to 30 days after surgery

Number of days spent

  • in the ICU during the index postoperative stay
  • in the hospital for the index surgical admission.
Up to 30 days after surgery
In-hospital mortality and 30-day mortality
Zeitfenster: Up to 30 days after surgery

Proportion of participants who die

  • before discharge from the index hospitalization
  • within 30 days after surgery, based on hospital records and, where available, follow up information.
Up to 30 days after surgery
Safety outcomes (CTCAE v6.0)
Zeitfenster: From the index hospitalization through 30 days after surgery
Incidence of cardiovascular, hematologic, metabolic, and neuropsychiatric adverse events with emphasis on thrombotic events, serious arrhythmias, severe hypertensive reactions, and events compatible with serotonin syndrome
From the index hospitalization through 30 days after surgery

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in body weight
Zeitfenster: From preoperative baseline to hospital discharge, assessed up to 30 days after surgery.
Difference in body weight (kg) between baseline and discharge.
From preoperative baseline to hospital discharge, assessed up to 30 days after surgery.
Change in mid-upper arm circumference
Zeitfenster: From preoperative baseline assessment to the day of hospital discharge, assessed up to 30 days after surgery
Difference in mid upper arm circumference (cm) as a simple anthropometric marker of muscle mass.
From preoperative baseline assessment to the day of hospital discharge, assessed up to 30 days after surgery
Change in fat-free mass (FFM)
Zeitfenster: Postoperative Day 6-10 or at hospital discharge, whichever occurs first
Difference in FFM (kg) between baseline and postoperative day 6-10 (or discharge). For participants in whom bioelectrical impedance analysis (BIA) is performed as part of extended clinical assessment.
Postoperative Day 6-10 or at hospital discharge, whichever occurs first
Change in skeletal muscle mass (SMM)
Zeitfenster: Postoperative Day 6-10
Difference in SMM (kg) between baseline and postoperative day 6-10 (or discharge). For participants in whom bioelectrical impedance analysis (BIA) is performed as part of extended clinical assessment.
Postoperative Day 6-10
Change in skeletal muscle mass index (SMMI)
Zeitfenster: Postoperative Day 6-10 or at hospital discharge, whichever occurs first
Difference in SMMI (kg/m²) between baseline and postoperative day 6-10 (or discharge). For participants in whom bioelectrical impedance analysis (BIA) is performed as part of extended clinical assessment.
Postoperative Day 6-10 or at hospital discharge, whichever occurs first
Change in phase angle
Zeitfenster: Postoperative Day 6-10 or at hospital discharge, whichever occurs first
Difference in phase angle (degrees) between baseline and postoperative day 6-10 (or discharge).For participants in whom bioelectrical impedance analysis (BIA) is performed as part of extended clinical assessment.
Postoperative Day 6-10 or at hospital discharge, whichever occurs first
Change in Nutritional Risk Screening 2002 (NRS-2002) score from baseline to discharge
Zeitfenster: From preoperative baseline assessment to the day of hospital discharge, assessed up to 30 days after surgery
Difference in Nutritional Risk Screening 2002 (NRS-2002) total score between baseline (preoperative assessment) and the day of hospital discharge. The NRS-2002 total score ranges from 0 to 7; higher scores indicate greater nutritional risk. For reporting, present mean (SD) change and number (%) of participants with clinically relevant change (e.g., change ≥1 point).
From preoperative baseline assessment to the day of hospital discharge, assessed up to 30 days after surgery
Change in Global Leadership Initiative on Malnutrition (GLIM) malnutrition severity category from baseline to discharge
Zeitfenster: From preoperative baseline assessment to the day of hospital discharge, assessed up to 30 days after surgery
Change in malnutrition severity category as defined by the Global Leadership Initiative on Malnutrition (GLIM) criteria between the preoperative baseline assessment and the day of hospital discharge. GLIM categories to be reported: No malnutrition, Moderate malnutrition, Severe malnutrition. For results reporting, present the number and proportion of participants in each GLIM category at baseline and at discharge, and the number and proportion of participants with a change in category (e.g., Moderate → Severe, Severe → Moderate, Any worsening, Any improvement).
From preoperative baseline assessment to the day of hospital discharge, assessed up to 30 days after surgery
Change in Patient-Generated Subjective Global Assessment (PG-SGA) total score from baseline to discharge
Zeitfenster: From preoperative baseline assessment to the day of hospital discharge, assessed up to 30 days after surgery
Difference in Patient-Generated Subjective Global Assessment (PG-SGA) total score between baseline (preoperative assessment) and the day of hospital discharge. PG-SGA is a validated nutritional assessment instrument; higher total scores indicate worse nutritional status. For results reporting, present mean (SD) change and median (IQR), and report the number and proportion of participants with a clinically meaningful change (predefined in the SAP; e.g., change ≥2 points).
From preoperative baseline assessment to the day of hospital discharge, assessed up to 30 days after surgery
Time to achievement of enteral nutrition ≥60-70% of calculated energy requirement
Zeitfenster: From initiation of postoperative nutritional support up to 30 days after surgery
Number of days from initiation of postoperative nutritional support to the first day on which ≥60-70% of calculated daily energy requirements are delivered via the enteral route, sustained according to local practice. Calculated energy targets follow institutional nutritional protocols (typically ~25-30 kcal/kg/day).
From initiation of postoperative nutritional support up to 30 days after surgery

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Arma Ltd.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Oktober 2026

Primärer Abschluss (Geschätzt)

31. Oktober 2028

Studienabschluss (Geschätzt)

1. März 2029

Studienanmeldedaten

Zuerst eingereicht

18. April 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

31. Mai 2026

Zuerst gepostet (Tatsächlich)

3. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

31. Mai 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • ARMA-GIDNUT-O-2026-01

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

IPD might not be shared due to national law

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren